MarketCap
Facebook
X
Telegram
Midatech Pharma plc DSO Ratio | MTP
Annual DSO Ratio Midatech Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 204 | 981 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 981 | 204 | 593 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Halozyme Therapeutics
HALO
|
93.4 | $ 103.0 | 0.08 % | $ 12.3 B |  USA |
 |
Hutchison China MediTech Limited
HCM
|
93.9 | $ 15.34 | 0.1 % | $ 13.2 B |  China |
 |
Aptorum Group Limited
APM
|
94 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
138 | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
71.1 | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
59.5 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
88.7 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
79.3 | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
6.94 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | - | - | $ 5.18 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
7.32 | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Cara Therapeutics
CARA
|
81.1 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
24.7 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
966 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
81.5 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
10.3 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
157 | - | -5.68 % | $ 8.28 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
202 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
541 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
19.8 | - | - | $ 889 M | USA |
 |
Amicus Therapeutics
FOLD
|
62.3 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
76.1 | - | - | $ 528 M | USA |
 |
GlycoMimetics
GLYC
|
303 | - | 9357.83 % | $ 1.01 B | USA |
 |
Happiness Biotech Group Limited
HAPP
|
5.46 | - | 1.35 % | $ 17.8 M | China |
 |
Novavax
NVAX
|
34.9 | $ 10.15 | -6.8 % | $ 1.64 B | USA |